Expression of FAK is elevated in a number of tumor types (reviewed in McLean et al., 2005), and FAK inhibitors are being developed as potential cancer therapeutics (Roberts et al., 2008; Shapiro et al., 2014). This evidence concerns the gene PTK2 and cancer.